Lohman-Payne B, Sandifer T, OhAinle M, Crudder C, Lynch J, Omenda M M, Maroa J, Fowke K, John-Stewart G C, Farquhar C
Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya; Department of Medicine, University of Washington, Seattle, Washington, USA; Department of Global Health, University of Washington, Seattle, Washington, USA.
Clin Exp Immunol. 2014 Oct;178(1):86-93. doi: 10.1111/cei.12386.
In-utero exposure to HIV-1 may affect the immune system of the developing child and may induce HIV-1-specific immune responses, even in the absence of HIV-1 infection. We evaluated lymphoproliferative capacity at birth among 40 HIV-1-uninfected infants born to HIV-1-infected mothers and 10 infants who had acquired HIV-1 in utero. Cord blood mononuclear cells were assayed using [(3) H]-thymidine incorporation for proliferation in response to HIV-1 p55-gag and the control stimuli phytohaemagglutinin (PHA), Staphylococcus enterotoxin B (SEB) and allogeneic cells. In response to HIV-1 p55-gag, eight (20%) HIV-1-exposed, uninfected (EU) infants had a stimulation index (SI) ≥ 2 and three (30%) in-utero HIV-1 infected infants had SI ≥2. The frequency and magnitude of responses to HIV-1 p55-gag were low overall, and did not differ statistically between groups. However, proliferative responses to control stimuli were significantly higher in EU infants than in infants infected in utero, with a median SI in response to PHA of 123 [interquartile range (IQR) 77-231] versus 18 (IQR 4-86) between EU and infected infants, respectively (P < 0·001). Among infected infants, gestational maturity was associated with the strength of HIV-1 p55-gag response (P < 0·001); neither maternal nor infant HIV-1 viral load was associated. In summary, EU and HIV-1-infected infants mounted HIV-1-specific lymphoproliferative responses at similar rates (20-30%), and although global immune function was preserved among EU infants, neonatal immune responses were significantly compromised by HIV-1 infection. Such early lymphoproliferative compromise may, in part, explain rapid progression to AIDS and death among HIV-1-infected infants.
子宫内暴露于HIV-1可能会影响发育中儿童的免疫系统,甚至在没有HIV-1感染的情况下也可能诱导HIV-1特异性免疫反应。我们评估了40名HIV-1感染母亲所生的未感染HIV-1的婴儿以及10名在子宫内感染HIV-1的婴儿出生时的淋巴细胞增殖能力。使用[(3)H]-胸腺嘧啶核苷掺入法检测脐血单个核细胞对HIV-1 p55-gag以及对照刺激物植物血凝素(PHA)、葡萄球菌肠毒素B(SEB)和异基因细胞的增殖反应。在对HIV-1 p55-gag的反应中,8名(20%)暴露于HIV-1但未感染(EU)的婴儿刺激指数(SI)≥2,3名(30%)子宫内感染HIV-1的婴儿SI≥2。总体而言,对HIV-1 p55-gag的反应频率和幅度较低,两组之间无统计学差异。然而,EU婴儿对对照刺激物的增殖反应显著高于子宫内感染的婴儿,EU婴儿和感染婴儿对PHA反应的SI中位数分别为123[四分位间距(IQR)77 - 231]和18(IQR 4 - 86)(P < 0.001)。在感染婴儿中,胎龄与HIV-1 p55-gag反应强度相关(P < 0.001);母亲和婴儿的HIV-1病毒载量均无相关性。总之,EU婴儿和HIV-1感染婴儿产生HIV-1特异性淋巴细胞增殖反应的比率相似(20% - 30%),虽然EU婴儿的整体免疫功能得以保留,但HIV-1感染显著损害了新生儿的免疫反应。这种早期淋巴细胞增殖受损可能部分解释了HIV-1感染婴儿快速进展至艾滋病和死亡的原因。